Mary-Margaret Zablocki

This inventor holds 48 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in HDAC Inhibitors. Top assignees: Forma Therapeutics, Inc., Valo Health, Inc., Valo Early Discovery, Inc.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary-Margaret Zablocki. Retrieved from https://idiyas.com/inventor/mary-margaret-zablocki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 48 (Patent Applications = 5)

% Patents Active = 97.9

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 8.5

ph-index = 14

Forward Citations = 430(Granted Patents)

Company Filing History:

30 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

HDAC Inhibitors

Ubiquitin-Specific Protease

Hydroxamic Acids

Bicyclic Compounds

Alpha-Cinnamide

Fatty Acid Synthase

Carboxamides

Amido Compounds

Spiro Compounds

Fused Bicyclic

Indanes

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

2. 12213969 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2025-02-04),

3. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

4. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

5. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

6. 11730721 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors (2023-08-22),

7. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors (2022-12-13),

8. 11414392 - [6,6] fused bicyclic HDAC8 inhibitors (2022-08-16),

9. 11299484 - Inhibiting fatty acid synthase (FASN) (2022-04-12),

10. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-22),

11. 11274085 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

12. 11274084 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

13. 10988450 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2021-04-27),

14. 10988441 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2021-04-27),

15. 10875848 - Inhibiting fatty acid synthase (FASN) (2020-12-29),

Title: **Mary-Margaret Zablocki: Innovator in Therapeutic Modulation**

Introduction

Mary-Margaret Zablocki is an accomplished inventor based in Revere, Massachusetts, with a remarkable portfolio that includes 47 patents. Her contributions have significantly advanced the field of medicinal chemistry, particularly in the development of innovative treatments for various diseases.

Latest Patents

Among her notable inventions, two recent patents stand out. The first is for "2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors." This invention focuses on inhibiting histone deacetylases (HDACs), particularly HDAC6, aiming to treat a range of diseases including cell proliferative conditions like cancer, various neurological disorders, and autoimmune diseases. The second patent is titled "Carboxamides as ubiquitin-specific protease inhibitors." This patent describes modulators that inhibit pathways such as USP28 and USP25, with potential applications in cancer treatment and other conditions.

Career Highlights

Mary-Margaret has played a pivotal role in the pharmaceutical industry, holding positions at prominent companies such as Forma Therapeutics, Inc. and Valo Health, Inc. Her work at these institutions has not only propelled her career but also facilitated substantial advancements in therapeutic innovations.

Collaborations

Throughout her career, Mary-Margaret has collaborated with talented colleagues including Xiaozhang Zheng and Pui Yee Ng. These partnerships have been instrumental in combining expertise and driving forward the research and development of novel therapeutic agents.

Conclusion

Mary-Margaret Zablocki’s extensive patent portfolio and contributions to medicinal chemistry underscore her status as a leading inventor in the field. Her work continues to pave the way for innovative treatments that address critical health challenges, reflecting her commitment to advancing science and improving patient outcomes.

Profile summary based on public USPTO records.